Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite ...
The phase 3 clinical trial of CAN-2409 in intermediate-to-high-risk, localized prostate cancer met its primary endpoint, by demonstrating statistically significant improvement in disease-free survival ...
UCSF scientists have developed a “molecular GPS” to guide immune cells into the brain and kill tumors without harming healthy tissue. It is the first living cell therapy that can navigate through the ...